-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $619

Benzinga·11/03/2026 11:42:24
Listen to the news
Cantor Fitzgerald analyst Carter Gould maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $595 to $619.